ADC Target Nanobody Discovery: A Guide to Target Selection and Candidate Screening

For an antibody–drug conjugate (ADC), a promising target must do more than appear on a disease-associated cell: it should be accessible, sufficiently selective, and able to support delivery of the linked payload. In nanobody discovery, we recommend defining the intended veterinary indication and species first, then screening candidates for target binding, cell-surface recognition, internalization, and developability. A nanobody is typically about 12–15 kDa, substantially smaller than a conventional IgG antibody at roughly 150 kDa, but size alone does not establish better tumor penetration or ADC performance. The right choice depends on the target, conjugation design, disease model, and evidence generated at each stage.

If you want to learn more, please visit our website.

Key Takeaways

• Start with the disease context, target biology, and intended animal species rather than selecting a target from expression data alone.
• Screen nanobody candidates in stages: binding, cell-surface recognition, internalization, selectivity, and developability.
• Use species-relevant samples or models when possible, and distinguish cross-reactivity from proven therapeutic suitability.
• Agree on deliverables, assays, and project scope with a discovery supplier before requesting a quote.

Who This Guide Is For

This guide is for veterinary pharmaceutical and biotechnology teams assessing nanobody-based ADC discovery for animal health applications. It is also relevant to researchers who need to compare targets, plan an early screening cascade, or prepare a project brief for a custom discovery partner. The recommendations are intended for early research planning, not as a substitute for veterinary, regulatory, or clinical evaluation.

Veterinary oncology projects may involve different species, tumor types, available samples, and model systems. A target supported by data in one species should not be assumed to have the same expression pattern or biological role in another. We therefore treat species relevance as an early design question, not a final validation step.

Understanding Target Selection for Nanobody ADCs

An ADC combines a targeting molecule with a cytotoxic or otherwise active payload through a chemical linker. The targeting molecule is intended to bind an antigen, while the linker and payload contribute to delivery and activity; the complete construct must be evaluated as a system. A nanobody can provide a compact binding domain, but its suitability depends on its binding properties and on the behavior of the conjugated molecule.

What Makes a Target Worth Evaluating?

Begin by asking whether the target is present on the relevant disease cells and accessible from outside the cell. For many ADC designs, internalization after binding is an important property to investigate because it can affect intracellular payload delivery. However, the desired trafficking behavior can depend on the payload, linker, and mechanism of action, so internalization should be measured rather than presumed.

Target selectivity matters alongside abundance. Expression on healthy tissues may create an on-target safety concern, while expression that varies between lesions or patients may limit the fraction of cells that can be addressed. Public datasets can help form a shortlist, but project decisions should be checked against relevant veterinary samples and validated assays where available.

Types of Target and Candidate Considerations

Potential targets may include cell-surface proteins, lineage-associated antigens, or disease-associated markers. The most practical category depends on whether the target is exposed on intact cells, whether suitable reagents and samples are available, and whether expression can be distinguished between diseased and normal tissues. Soluble antigens may be useful for discovery or binding assays, but binding to a purified protein does not by itself demonstrate recognition of the native cell-surface target.

Candidate nanobodies can be compared by affinity, specificity, epitope, cell binding, internalization, and developability. Affinity is only one part of the selection: a very strong interaction does not automatically produce better cell targeting or ADC activity. Candidate format, conjugation site, linker chemistry, and payload can alter behavior, so an unconjugated binder should not be treated as proof of a successful ADC.

Match the Target to the Veterinary Application

Define the species and indication before choosing discovery materials or assays. For a canine oncology project, for example, a human target reagent may support an initial assay only if its relevance to the canine antigen is established. Species cross-reactivity should be measured with the appropriate ortholog or species-derived cells, and sequence similarity alone should not be treated as evidence of functional cross-reactivity.

Where possible, build a screening panel that includes target-positive disease cells, target-negative controls, and non-disease or normal-cell comparators relevant to the intended species. A practical initial design might assess at least 3 cell groups—target-positive, target-negative, and normal-cell controls—before advancing candidates. This is a proposed screening structure, not a universal requirement; sample availability and assay goals should determine the final panel.

A Selection Framework for Target and Candidate Screening

1. Define the Biological and Commercial Brief

Record the species, indication, intended patient population, target hypothesis, and available biological materials. Specify whether the project seeks a binder to a purified antigen, a native-cell binder, or candidates suitable for further ADC evaluation. Also identify constraints such as cross-reactivity needs, assay access, and the intended research stage.

If you want to learn more, please visit our website NBbiolab.

2. Validate Target Relevance and Accessibility

Review expression evidence in disease and normal tissues, then confirm that the antigen is accessible on intact cells using an appropriate assay. Check whether target levels vary across samples and whether the target is shed or present in soluble form if that could affect interpretation. When veterinary data are limited, document the evidence gap and plan additional validation rather than assuming the target behaves like its human counterpart.

3. Screen Binding and Specificity

Use orthogonal assays where practical, such as a purified-protein binding assay and a cell-based assay. Include negative controls and assess nonspecific binding to help distinguish target-specific recognition from assay artifacts. A recommended early screening window could use measurements at 4°C for surface binding and at 37°C for a separate internalization assessment, with incubation times selected and validated for the assay.

4. Evaluate Internalization and Selectivity

Measure whether candidate-bound target enters cells under conditions relevant to the planned construct. Use suitable controls to separate internalization from surface retention or signal loss, and interpret results in the context of the detection method. Compare activity across target-positive and control cells, while remembering that in vitro selectivity does not establish safety in an animal.

5. Assess Developability Before ADC Progression

Review expression, purity, aggregation, stability, and sequence liabilities using assays appropriate to the project stage. Then evaluate how candidate format and conjugation strategy may affect binding and behavior. A candidate that binds well but is difficult to produce or behaves inconsistently may be a less practical lead than a slightly weaker, more robust alternative.

Supplier Evaluation, Pricing, MOQ, and Lead Time

Custom discovery pricing, minimum order quantities, and timelines depend on the project scope, starting materials, assay complexity, and agreed deliverables. We do not recommend relying on a generic lead-time or price estimate without a written scope. Ask whether the proposal includes target-reagent review, species-specific assay design, candidate sequence information, binding characterization, cell-based screening, and any follow-up work needed to assess ADC suitability.

When evaluating a supplier, request clarity on experimental stages, decision gates, sample requirements, data formats, ownership terms, and what happens if the target reagent or assay does not perform as expected. Confirm whether the supplier can work with veterinary species materials relevant to your program, and which capabilities are included versus separately scoped. These details make quotations easier to compare and reduce the risk of receiving binders without the evidence needed for progression.

Questions to Ask a Discovery Partner

• Can the proposed workflow test binding to the native target in the intended animal species?
• Which controls and orthogonal assays will distinguish target-specific cell binding from nonspecific signal?
• Are internalization, cross-reactivity, and developability assessments included or optional?
• What candidate data, sequences, and materials are delivered at each project milestone?
• How are project changes, assay failures, and additional screening costs handled?

How NBbiolab Can Support Your Project

At NBbiolab, we approach ADC target nanobody discovery as a staged evaluation rather than a single binding screen. We can discuss project requirements such as target selection, veterinary species relevance, screening strategy, and candidate characterization, then align the proposed work with the materials and evidence available. The final scope should be confirmed against your target, indication, assay needs, and desired deliverables.

To begin a discussion, prepare a short brief covering the target, animal species, intended application, available antigen or cells, and the properties you need in a candidate. If you have existing expression or cross-reactivity data, sharing the methods and limitations can help identify useful next experiments. Contact NBbiolab to discuss a discovery plan and request a project-specific proposal.

Conclusion

The best ADC nanobody target is not simply the antigen with the strongest reported expression or the binder with the highest measured affinity. It is a target supported by relevant veterinary evidence and a candidate that demonstrates cell-surface recognition, suitable selectivity, and properties compatible with the intended ADC design. Start by defining the species and indication, validate target accessibility, and use staged screening with appropriate controls.

Your next step is to assemble the target and species information, available samples, and required deliverables into a project brief. Then compare discovery proposals by their assays, decision gates, data ownership, and candidate characterization—not price alone. This gives your team a clearer basis for deciding whether and how to advance a nanobody candidate toward ADC evaluation.